Functional Dyspepsia (FD)
Functional dyspepsia is characterized by a number of symptoms associated with upper intestinal discomfort. In 2006, a specialist panel of clinicians issued a report entitled Rome III recommending that certain of these symptoms, including mid-to-upper abdominal discomfort characterized by postprandial fullness, early satiety or upper abdominal bloating, be classified as postprandial distress syndrome, or PDS. These symptoms are believed to be associated with deficiencies in motility of the upper gastrointestinal tract. Naronapride is being developed for the treatment of PDS. No currently marketed therapy is considered to be an optimal treatment for this condition. Functional dyspepsia is present in 7.2% of persons worldwide (Source: Sperber 2021).